Sell Suven Pharmaceuticals; target of Rs 571: Geojit
Geojit is bearish on Suven Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 571 in its research report dated February 29, 2024.01-03-2024
01-03-2024
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Concall Invitation29-02-2024
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation29-02-2024
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Outcome of the Board Meeting started at 17.30 and ended at 18.3029-02-2024
Suven Pharmaceuticals Ltd - 543064 - Board Meeting Outcome for Outcome Of The Board Meeting
Outcome of the Board Meeting29-02-2024
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
We wish to inform you that the Nomination and Remuneration Committee of the Suven Pharmaceuticals Limited, considered and approved the grant of 65,94,308 stock options at its meeting held on 24th February 2024 under the Suven Pharmaceuticals Limited- Employee Stock Option Plan 2023 (ESOP 2023) to the eligible employees of the Company24-02-2024
Suven Pharmaceuticals Ltd - 543064 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 regarding completion of Pre-Approval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections by USFDA for Active Pharmaceutical Ingredents (API) and Formulation facilities (Unit-3 and Unit-5, Respectively) in Pashamylaram, Hyderabad.23-02-2024
Suven Pharmaceuticals Ltd - 543064 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Disclosure of Voting Results - Postal Ballot13-02-2024
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the earnings conference call for the quarter and nine months ended December 31, 202309-02-2024